The extension of the collaboration follows the launch of the ready-to-use Gyrolab CHO HCP and E. coli HCP kits, developed through a licensing and supply agreement with Cygnus
Gyros Protein Technologies, a producer of automated nanoliter-scale immunoassays along with peptide synthesisers and reagents, has announced the next phase of an ongoing collaboration with Cygnus Technologies, introducing the HEK 293 HCP immunoassay. The assay reagent set for Gyrolab is the first of a planned range of bioprocess impurity reagent sets optimised for the platform, to be developed by Cygnus as part of the expanded collaboration.
The extension of the collaboration follows the launch of the ready-to-use Gyrolab CHO HCP and E. coli HCP kits, developed through a licensing and supply agreement with Cygnus.The assay reagent set for detects residual host cell protein (HCP) from HEK 293 cells, a cell line commonly used in viral vector production for cell and gene therapies as well as in manufacturing of vaccines. These combine to form the HEK 293 HCP solution for Gyrolab. The automated nanoliter-scale immunoassay is designed to support fast development and streamlined process transfer. This enables researchers to generate more data in less time for more analytical applications, the company says.
“The collaboration with Cygnus Technologies is an exciting step for Gyros Protein Technologies, underscoring our commitment to provide leading-edge automated analysis solutions that support bioprocessing and manufacturing,” said Mark Vossenaar, VP, General Manager, Biopharmaceutical Development Division at Mesa Labs. “There is a real need for analytical tools that support fast turn-around time and small sample volume, to accelerate viral vector bioprocess workflows and reduce time to market. HEK 293 HCP assay reagent set for Gyrolab is the first of this new, high quality range, and we hope to announce further releases in the near future.”
“Gyrolab is an ideal platform with which to partner, to provide an automated solution that can produce high quality, reproducible results in the bioprocess analytics space,” said Christine Dolan, COO, Cygnus Technologies.